Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912090 | 0.94 | CYP2D6 (0.65) | CYP2D6KDM4EATMMAPTTHRB | |
| SCHEMBL26913055 | 0.86 | CYP2D6 (0.60) | CYP2D6KDM4EATMMAPTTHRB | |
| SCHEMBL24331243 | 0.83 | CYP2D6 (0.52) | CYP2D6KDM4EATMALDH1A1BRD4 | |
| SCHEMBL30611141 | 0.83 | CYP2D6 (0.52) | CYP2D6KDM4EATMALDH1A1BRD4 | |
| SCHEMBL24330427 | 0.78 | CYP2D6 (0.48) | CYP2D6KDM4EATMMAPTTHRB | |
| SCHEMBL24331227 | 0.78 | CYP2D6 (0.48) | CYP2D6KDM4EATMMAPTTHRB | |
| SCHEMBL30611150 | 0.78 | CYP2D6 (0.48) | CYP2D6KDM4EATMMAPTTHRB | |
| SCHEMBL26912244 | 0.77 | CYP2D6 (0.46) | CYP2D6KDM4EMAPTTHRBPRKDC | |
| SCHEMBL26912033 | 0.77 | PRKDC (0.60) | HSD11B1PRKDC | |
| SCHEMBL26911815 | 0.77 | LRRK2 (0.50) | CYP2D6KDM4EMAPTTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | CYP2D6 4869/4885KDM4E 4326/4885ATM 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.